Indirect Comparative Effectiveness of Treatments for Older Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (NIC): Combinations Glasdegib plus Low-Dose Cytarabine (GLAS plus LDAC) vs Decitabine or Venetoclax plus LDAC

被引：0

作者：

Tremblay, G. ^{[1
]}

Westley, T. ^{[1
]}

Bell, T. J. ^{[2
]}

Cappelleri, J. C. ^{[3
]}

Chan, G. ^{[4
]}

Hearnden, J. ^{[1
]}

Forsythe, A. ^{[1
]}

机构：

[1] Purple Squirrel Econ, New York, NY USA

[2] Pfizer Inc, New York, NY USA

[3] Pfizer Inc, Groton, CT 06340 USA

[4] Pfizer Inc, Collegeville, PA USA

来源：

关键词：

acute myeloid leukemia; decitabine; glasdegib; indirect treatment comparison; Low-Dose Cytarabine; stimulated treatment comparison; Venetoclax;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH19-PO-0

引用

页码：39 / 39

页数：1